Purple Biotech (PPBT) Net Cash Flow (2014 - 2026)
Purple Biotech's (PPBT) quarterly Net Cash Flow came in at -$384000.0 in Q2 2026, up 64.15% year-over-year from -$233938.6 in Q2 2025, and up 87.77% quarter-over-quarter from -$3.1 million in Q1 2026.
Powered by 
Analysis
Purple Biotech (PPBT) Net Cash Flow (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Net Cash Flow for 12 consecutive years, with -$384000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Net Cash Flow rose 64.15% year-over-year to -$384000.0 in Q2 2026; TTM through Jun 2026 was $474000.0, a 126.12% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 118.48% from the prior year.
- Net Cash Flow was -$384000.0 for Q2 2026 at Purple Biotech, up from -$3.1 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $12.7 million in Q1 2022 and troughed at -$9.4 million in Q2 2022.
- A 5-year average of -$311166.7 and a median of -$1.1 million in 2024 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 1565.66% in 2022, down 3228.0% in 2022.
- Over 5 years, Net Cash Flow stood at $3.9 million in 2022, then plunged by 117.09% to -$662000.0 in 2023, then soared by 396.53% to $2.0 million in 2024, then plunged by 144.52% to -$874000.0 in 2025, then surged by 56.06% to -$384000.0 in 2026.
- The last three Net Cash Flow figures came in at -$384000.0 (Q2 2026), -$3.1 million (Q1 2026), and -$874000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.46 Bn | 192.47 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 179.92 Bn | 176.75 Bn | 6.22 Bn | -4.43 Bn |
| 3 | Vertex Pharmaceuticals | 131.37 Bn | 123.51 Bn | 2.84 Bn | 652.90 Mn |
| 4 | Regeneron Pharmaceuticals | 81.86 Bn | 73.87 Bn | 3.93 Bn | -504.30 Mn |
| 5 | Argenx Se | 60.29 Bn | 55.10 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.76 Bn | 48.62 Bn | 52.00 Mn | -183.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.16 Bn | 29.85 Bn | 992.69 Mn | -496,000.00 |
| 8 | Biogen | 31.90 Bn | 30.62 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 29.13 Bn | 29.13 Bn | 1.16 Mn | -170.75 Mn |
| 10 | Purple Biotech | 291,843.46 | 291,843.46 | - | -384,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -384,000.00 |
| Mar 31, 2026 | -3.14 Mn |
| Dec 31, 2025 | -874,000.00 |
| Sep 30, 2025 | 4.87 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Mar 31, 2025 | -1.62 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Sep 30, 2024 | -1.09 Mn |
| Jun 30, 2024 | -3.46 Mn |
| Mar 31, 2024 | -4.50 Mn |
| Dec 31, 2023 | -662,000.00 |
| Sep 30, 2023 | -2.08 Mn |
| Jun 30, 2023 | -4.66 Mn |
| Mar 31, 2023 | 6.80 Mn |
| Dec 31, 2022 | 3.87 Mn |
| Sep 30, 2022 | -2.88 Mn |
| Jun 30, 2022 | -9.38 Mn |
| Mar 31, 2022 | 12.68 Mn |
| Dec 31, 2021 | 235,000.00 |
| Sep 30, 2021 | -1.39 Mn |